Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes

被引：0
作者：
Horowitz, M. [1 ]
Flint, A. [2 ]
Doran, S.
Rasmussen, M. F. [2 ]
Kapitza, C. [3 ]
Andreasen, A. H. [2 ]
Jones, K. L. [1 ]
Zdravkovic, M. [2 ]
Chapman, I. M. [1 ]
机构：
[1] Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] Profil Inst Stoffwechselforsch GmbH, Neuss, Germany
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
889
引用
收藏
页码：S355 / S355
页数：1
相关论文
共 50 条
[41]   Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus [J].
Vilsboll, T. ;
Brock, B. ;
Perrild, H. ;
Levin, K. ;
Lervang, H. -H. ;
Kolendorf, K. ;
Krarup, T. ;
Schmitz, O. ;
Zdravkovic, M. ;
Le-Thi, T. ;
Madsbad, S. .
DIABETIC MEDICINE, 2008, 25 (02) :152-156
[42]   The once-daily human GLP-1 analogue liraglutide increases the beta cell mass in normoglycaemic mice by directly accelerating cell differentiation and proliferation [J].
Shimoda, M. .
DIABETOLOGIA, 2009, 52 :S34-S35
[43]   The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects [J].
Jiang, Ji ;
Zhang, Jianyan ;
Jacobsen, Lisbeth V. ;
Hu, Pei .
JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12) :1620-1627
[44]   Liraglutide, a human GLP-1 analogue, reduces systolic blood pressure in subjects with type 2 diabetes [J].
Colagiuri, S. ;
Frid, A. ;
Zdravkovic, M. ;
Le-Thi, T. D. ;
Vaag, A. ;
Garber, A. ;
Zinman, B. .
DIABETOLOGIA, 2008, 51 :S359-S360
[45]   Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride both as add-on to metformin [J].
Frid, Anders ;
Nauck, Michael A. ;
Hermansen, Kjeld ;
Kolotkin, Ronette L. ;
Hammer, Mette ;
Zdrav-Kovic, Milan ;
Matthews, David .
DIABETES, 2008, 57 :A574-A575
[46]   Pharmacokinetic modelling of the once-daily human GLP-1 analogue liragiutide in healthy volunteers and comparison to exenatide [J].
Jonker, Daniel ;
Toft, Anders D. ;
Kristensen, Peter ;
Knudsen, Lotte ;
Watson, Estelle .
DIABETES, 2007, 56 :A160-A160
[47]   Liraglutide, a Once-Daily Human GLP-1 Analog, Reduces Systolic Blood Pressure with Minimal Impact from Weight Loss in Subjects with Type 2 Diabetes. [J].
Henry, R. R. ;
Fonseca, V. ;
Tabanera y Palacios, R. ;
Brett, J. ;
Plutzky, J. .
ENDOCRINE REVIEWS, 2010, 31 (03)
[48]   Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (vol 36, pg 890, 2012) [J].
Astrup, A. ;
Carraro, R. ;
Finer, N. ;
Harper, A. ;
Kunesova, M. ;
Lean, M. E. J. ;
Niskanen, L. ;
Rasmussen, M. F. ;
Rissanen, A. ;
Roessner, S. ;
Savolainen, M. J. ;
Van Gaal, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :890-890
[49]   The once-daily human GLP-1 analog liraglutide substantially reduces HbA1c in subjects with type 2 diabetes, irrespective of HbA1c at baseline [J].
Nauck, Michael ;
Brandle, Michael ;
Vaag, Allan ;
Colagiuri, Stephen ;
Schmitz, Ole ;
Zdravkovic, Milan ;
Hermansen, Kyeld .
DIABETES, 2008, 57 :A594-A594
[50]   Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].
A Astrup ;
R Carraro ;
N Finer ;
A Harper ;
M Kunesova ;
M E J Lean ;
L Niskanen ;
M F Rasmussen ;
A Rissanen ;
S Rössner ;
M J Savolainen ;
L Van Gaal .
International Journal of Obesity, 2013, 37 :322-322
12345